ImmunoVec Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$12.7M
- Investors
-
8
ImmunoVec General Information
Description
Developer of in vivo cell engineering technology designed to precisely engineer targeted cell types within the human body through cell-type-specific gene expression. The company offers synthetic promoters, expression cassettes, viral and non-viral delivery systems, and polymeric and lipid nanoparticles, enabling researchers and biopharmaceutical companies to engineer targeted gene expression in specific cell types.
Contact Information
Website
www.immunovec.comCorporate Office
- 23110 Mariposa De Oro
- Malibu, CA 90265
- United States
Corporate Office
- 23110 Mariposa De Oro
- Malibu, CA 90265
- United States
ImmunoVec Timeline
ImmunoVec Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 14-Jul-2026 | $12.7M | Completed | Startup | ||
| 4. Grant | 08-Oct-2025 | Completed | Startup | |||
| 3. Grant | 04-Aug-2023 | Completed | Stealth | |||
| 2. Seed Round | 02-Mar-2022 | $4.3M | $4.3M | Completed | Stealth | |
| 1. Accelerator/Incubator | Completed | Stealth |
ImmunoVec Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ImmunoVec Patents
ImmunoVec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240287546-A1 | Enhancers and vectors | Pending | 16-Jun-2022 | ||
| AU-2023290161-A1 | Improved enhancers and vectors | Pending | 16-Jun-2022 | ||
| EP-4540396-A1 | Improved enhancers and vectors | Pending | 16-Jun-2022 | ||
| EP-4540396-A4 | Improved enhancers and vectors | Pending | 16-Jun-2022 | ||
| WO-2023244737-A1 | Improved enhancers and vectors | Inactive | 16-Jun-2022 | C12N15/86 |
ImmunoVec Signals
ImmunoVec Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Black Diamond Ventures | Venture Capital | Minority | ||
| ARPA-H | Government | |||
| California Institute for Regenerative Medicine | Government | |||
| Anthem Venture Partners | Venture Capital | Minority | ||
| Constellar Ventures | Family Office | Minority |
ImmunoVec FAQs
-
When was ImmunoVec founded?
ImmunoVec was founded in 2019.
-
Where is ImmunoVec headquartered?
ImmunoVec is headquartered in Malibu, CA.
-
What is the size of ImmunoVec?
ImmunoVec has 9 total employees.
-
What industry is ImmunoVec in?
ImmunoVec’s primary industry is Biotechnology.
-
Is ImmunoVec a private or public company?
ImmunoVec is a Private company.
-
What is the current valuation of ImmunoVec?
The current valuation of ImmunoVec is .
-
What is ImmunoVec’s current revenue?
The current revenue for ImmunoVec is .
-
How much funding has ImmunoVec raised over time?
ImmunoVec has raised $17M.
-
Who are ImmunoVec’s investors?
Black Diamond Ventures, ARPA-H, California Institute for Regenerative Medicine, Anthem Venture Partners, and Constellar Ventures are 5 of 8 investors who have invested in ImmunoVec.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process